CONTACT US

* After 68 weeks of weekly semaglutide treatment, participants experienced an average body weight reduction of 15%. The semaglutide group saw a 14.9% decrease from baseline, compared to just 2.4% in the placebo group. See details

* Obstructive Sleep Apnea: Achieving at least 10% weight loss is key to improving symptoms. Patients in the intensive lifestyle intervention (ILI) group lost an average of 10.8 kg (23.76 lbs) in one year, and their obstructive sleep apnea remission rate was three times higher than those in the diabetes support and education (DSE) group, who lost only 0.6 kg (1.32 lbs). See details

* Cardiovascular Disease Risk Factors: Improvements in triglycerides and systolic blood pressure can begin with as little as 2-5% weight loss. For diastolic blood pressure and HDL cholesterol, benefits are seen with a 5-10% reduction in body weight. See details

* Emotional Health & Confidence: Dietary interventions for obese individuals with depression may not only alleviate some depressive symptoms but also enhance their metabolic profile and reduce cardiovascular risks. See details

* Genetics and environmental factors work together to influence body weight, with research showing that obesity is 40% to 70% heritable. Over 244 genes have been identified that play a significant role in fat accumulation when overexpressed. See details

* Clinical trials have shown that a peptide found in GLP-1 medications can help regulate metabolism. See details

Safety info: GLP-1 medications are used to treat obesity or overweight (with weight-related problems), along with diet and exercise.They may have serious side effects, including possible thyroid tumors. Do not use if you or your family have a history of a type of thyroid cancer called MTC or MEN 2.